Year: 2024
Type: article
Abstract: , with no apparent resistance. Clovibactin outclasses current antibiotics such as vancomycin. Here, we discuss its efficacy, emphasize the need for new antibiotics owing to growing global antibiotic resistance, highlight its mode of action and possible benefits over current treatments. We also highlight the challenges involved in large-scale manufacturing and the status of continuing research to advance effective and less toxic derivatives.
Source: PubMed
DOI: 10.3205/dgkh000501
Author: Adeiza, Shuaibu Suleiman
Institutions: Ahmadu Bello University, Usmanu Danfodiyo University
Language: English
Subfield: Pharmacology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4404474342